AOP Orphan Pharmaceuticals AG (AOP Orphan) has taken over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm.
The AOP Orphan Group is the European pioneer in the field of special diseases with a complex management. With the takeover finalised, the health care group will concentrate on four therapeutic divisions: hemato-oncology, cardiology & pulmonology, neurology & metabolic disorders, and intensive care medicine. The company will continue to focus on developing holistic therapy solutions that place patients at the heart of the matter.
All existing jobs have been kept and form the basis for a growth strategy which should also create further jobs in the coming years. New chances and opportunities will also open up as AOP Orphan continues its consistent growth trajectory towards being a pan-European health care group with a focus on rare and complex diseases. Researching, developing, and marketing new products and services are geared towards the entire global market, which is already covered from Canada through to South America and Australia.
The Group intends to increase its revenues to one billion euros by 2030. AOP currently has various products for around 10 indications in the pipeline, including for septic shock, Huntington’s chorea (a functional disorder of the brain characterized by motor and behavioral problems) or chronic myeloid leukemia, a malignant disease of the bone marrow. As well as developing innovative therapies, the international team also works on medical devices and software solutions, e.g. for patients with pulmonary arterial hypertension (PAH). Patients are connected to the doctors treating them by an app which enables the dose of the drug which is administered using a pump to be controlled – precisely and tailored to the individual patient.
The AOP Orphan Group manufactures 80 percent of its drugs in Europe – an aspect which has become more and more relevant since the start of the COVID-19 pandemic. The AOP Orphan Group now has more than 20 subsidiaries and representative offices across the whole of Europe as well as in the United Arab Emirates and Israel.
The takeover of Amomed and SciPharm brings the research and development of drugs as well as the development of medical devices and patient services together under one roof, creating optimal conditions for developing integrated therapies. OrphaCare’s hotline, for example, is a key service in the everyday life of people suffering with PAH.
Professor Dr. Irene Lang, Head of the Pulmonary Hypertension Outpatient Clinic at Vienna’s General Hospital (AKH) said: “We as doctors very much appreciate this approach, as do the patients. Because it is important to ensure long-term treatment with a life-saving drug. This expert hotline is of great value and is now indispensable in providing care to patients.”
Andreas Steiner, CEO of AOP Orphan said: “From the beginning, it was our priority to preserve all existing jobs and we have done just that. By developing innovative therapies and a broader territorial presence, we are convinced that we will continue to generate significant growth.”